Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study

Olagunju, Adeniyi ORCID: 0000-0002-6588-5749, Anweh, Damien, Okafor, Ogechi, Dickinson, Laura ORCID: 0000-0001-5557-9396, Richman, Douglas ORCID: 0000-0003-0962-9254, Owen, Andrew ORCID: 0000-0002-9819-7651 and Adejuyigbe, Ebunoluwa ORCID: 0000-0002-8671-4965
(2019) Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study. Wellcome Open Research, 4. p. 34.

Access the full-text of this item by clicking on the Open Access link.


<h4>Background: </h4> Pregnancy and polymorphisms in drug disposition genes alter the clearance of key antiretrovirals used as part of regimens for prevention of mother-to-child transmission of HIV (PMTCT). The clinical significance of these in women initiating therapy late in pregnancy has not been investigated. The primary objective of the Viral and Antiretroviral Dynamics in HIV Mother-To-Child Transmission Fluids ( VADICT) study is to investigate viral and antiretroviral dynamics in matrices associated with mother-to-child transmission (MTCT) (plasma, genital fluid and breastmilk) in women (stratified by CYP2B6 genotypes) who initiate antiretroviral therapy (ART) before or early in pregnancy versus late in pregnancy or early postpartum. <h4>Methods: </h4>: A cohort of HIV-1 infected women who initiated ART containing 600 mg efavirenz before or early in pregnancy (n = 120), during the third trimester (n = 60), or early postpartum (n = 60) will be studied.  Eligible patients will be recruited from four hospitals in Benue State, North Central Nigeria and followed until the end of breastfeeding. Procedures at follow up visits will include sample collection for drug quantification and HIV-1 RNA and DNA in plasma, genital fluid and breastmilk; adherence monitoring; and newborn and infant assessment. Using newborn exposure to maternal efavirenz at birth for validation, prenatal pharmacogenetics of efavirenz will be explored using physiologically-based pharmacokinetic modelling. Three integrated methods will be used to monitor patterns and correlates of adherence across pregnancy and the breastfeeding period. A population pharmacokinetic-pharmacodynamic model will be developed to describe the observed data and simulate what to expect in women initiating ART containing 400 mg efavirenz (recently approved for non-pregnant adults) late in pregnancy or early postpartum. <h4>Discussion: </h4> This study will help in understanding residual MTCT in women receiving ART and reasons for the rise in MTCT risk during the breastfeeding period. Trial registration NCT03284645 (15/09/2017)

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 21 Feb 2020 16:42
Last Modified: 19 Jan 2023 00:01
DOI: 10.12688/wellcomeopenres.15072.1
Open Access URL:
Related URLs: